Nav: Home

Scientists discover drug that increases 'good' fat mass and function

January 17, 2017

SAN FRANCISCO, CA--January 17, 2017--Scientists at the Gladstone Institutes identified an FDA-approved drug that can create the elusive and beneficial brown fat. Mice treated with the drug had more brown fat, faster metabolisms, and less body weight gain, even after being fed a high-calorie diet. The researchers say the technique, which uses cellular reprogramming, could be a new way to combat obesity and type II diabetes.

Brown Fat Boosts Metabolism

Brown fat is different than the more commonly known white fat, which stores energy. In contrast, brown fat helps the body burn energy through heat. Infants are born with small amounts of brown fat, but as they age, most of it disappears. In adults, people with higher amounts of brown fat have lower body mass, and increasing brown fat by as little as 50 grams could lead up to a 10 to 20 pound weight loss in 1 year.

"Introducing brown fat is an exciting new approach to treating obesity and associated metabolic diseases, such as diabetes," said study first author Baoming Nie, PhD, a former postdoctoral scholar at Gladstone. "All current weight loss drugs control appetite, and there is nothing on the market that targets energy expenditure. If we can create additional stores of brown fat and boost its function in the body, we could burn off the energy stored in white fat more easily."

How to Create Brown Fat

In the new study, published in Cell Reports, scientists in the laboratory of Gladstone Senior Investigator Sheng Ding, PhD, used cellular reprogramming to convert muscle precursor cells and white fat cells into brown fat cells.

The researchers tested 20,000 chemicals until they found one that changed the identity of the cells most effectively. The winning chemical--an anti-cancer drug called bexarotene (Bex)--surprised the scientists, as it targets a protein that was not previously shown to be involved in generating brown fat.

Bex acts on a "master regulator" protein called retinoid X receptor (RXR), which controls a network of other cellular proteins. Activating RXR triggered a cascade of changes in muscle precursor cells and white fat that ultimately converted them into brown fat-like cells. Specifically, when RXR was stimulated by Bex, it turned on genes needed to produce brown fat and turned off genes linked to white fat or muscle.

Burn Energy, Prevent Weight Gain

To test how well Bex controls body weight, the scientists fed mice a high-calorie diet for 4 weeks, but they only treated half of the mice with the drug. The mice that were given Bex had more brown fat, burned more calories, had less body fat, and gained less weight than mice that were fed the same diet but were not given the drug.

"We're very excited about the prospect of using a drug to generate brown fat in the body," said Ding. "However, while Bex is very effective at creating brown fat cells, it is not a very specific drug, and there are several potential side effects that may arise from taking it. Our next task is to develop a safer, more targeted drug that only affects genes involved in creating brown fat."

Other Gladstone researchers on the study include Haixia Wang, Ke Li, Shibing Tang, Yu Zhang, and Tao Xu. Scientists from the Chinese Academy of Sciences, University of Hong Kong, and Nanjing University also took part in the research.
-end-
Funding was provided by the National Institute of Child Health and Human Development, National Heart, Lung, and Blood Institute, National Eye Institute, California Institute of Regenerative Medicine, National Basic Research Program of China, Chinese Academy of Sciences, and Science and Technology Planning Project of Guangdong Province.

About the Gladstone Institutes

To ensure our work does the greatest good, the Gladstone Institutes focuses on conditions with profound medical, economic, and social impact--unsolved diseases of the brain, the heart, and the immune system. Affiliated with the University of California, San Francisco, Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease.

Gladstone Institutes

Related Diabetes Articles:

The role of vitamin A in diabetes
There has been no known link between diabetes and vitamin A -- until now.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
Type 2 diabetes and obesity -- what do we really know?
Social and economic factors have led to a dramatic rise in type 2 diabetes and obesity around the world.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
New cause of diabetes
Although insulin-producing cells are found in the endocrine tissue of the pancreas, a new mouse study suggests that abnormalities in the exocrine tissue could cause cell non-autonomous effects that promotes diabetes-like symptoms.
The Lancet Diabetes & Endocrinology: Reducing sugar content in sugar-sweetened drinks by 40 percent over 5 years could prevent 1.5 million cases of overweight and obesity in the UK and 300,000 cases of diabetes
A new study published in The Lancet Diabetes & Endocrinology journal suggests that reducing sugar content in sugar sweetened drinks (including fruit juices) in the UK by 40 percent over five years, without replacing them with any artificial sweeteners, could prevent 500,000 cases of overweight and 1 million cases of obesity, in turn preventing around 300,000 cases of type 2 diabetes, over two decades.
Breastfeeding lowers risk of type 2 diabetes following gestational diabetes
Women with gestational diabetes who consistently and continuously breastfeed from the time of giving birth are half as likely to develop type 2 diabetes within two years after delivery, according to a study from Kaiser Permanente published today in Annals of Internal Medicine.

Related Diabetes Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...